Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
2.410
+0.470 (24.23%)
At close: Nov 4, 2024, 4:00 PM
2.430
+0.020 (0.83%)
After-hours: Nov 4, 2024, 7:59 PM EST

Company Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.

It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction.

Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tenaya Therapeutics, Inc.
Tenaya Therapeutics logo
Country United States
Founded 2016
IPO Date Jul 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 140
CEO Faraz Ali

Contact Details

Address:
171 Oyster Point Boulevard, Suite 500
South San Francisco, California 94080
United States
Phone 650 825 6990
Website tenayatherapeutics.com

Stock Details

Ticker Symbol TNYA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001858848
CUSIP Number 87990A106
ISIN Number US87990A1060
Employer ID 81-3789973
SIC Code 2836

Key Executives

Name Position
Faraz Ali M.B.A. Chief Executive Officer and Director
Dr. Deepak Srivastava M.D. Scientific Founder, Chairman of Scientific Advisory Board and Director
Dr. Whittemore G. Tingley M.D., PH.D. Chief Medical Officer
Dr. Eric N. Olson Ph.D. Scientific Founder and Member of Scientific Advisory Board
Dr. Bruce R. Conklin Scientific Founder
Dr. Saptarsi Haldar M.D. Scientific Founder
Dr. Sheng Ding Ph.D. Scientific Founder
Dr. Benoit G. Bruneau Ph.D. Scientific Founder
Chihiro Saito Senior Accounting and Financial Operations and Interim Principal Accounting Officer
Dr. Kee-Hong Kim Ph.D. Chief Technology Officer

Latest SEC Filings

Date Type Title
Sep 17, 2024 S-8 Securities to be offered to employees in employee benefit plans
Sep 16, 2024 8-K Current Report
Aug 16, 2024 144 Filing
Aug 16, 2024 144 Filing
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 25, 2024 8-K Current Report
Jun 27, 2024 8-K Current Report
May 31, 2024 8-K Current Report
May 14, 2024 10-Q Quarterly Report